中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2015年
2期
403-405
,共3页
魏德%魏成斌%黄绍松%洪文瑶
魏德%魏成斌%黃紹鬆%洪文瑤
위덕%위성빈%황소송%홍문요
诱骗受体-3%白细胞介素-17%胶质瘤
誘騙受體-3%白細胞介素-17%膠質瘤
유편수체-3%백세포개소-17%효질류
Decoy receptor-3%Interleukin-17%Glioma
目的 探讨诱骗受体-3(DcR-3)和白细胞介素-17(IL-17)在人脑胶质瘤中的表达及意义.方法 连续收集90例胶质瘤患者及脑外伤患者10例,应用酶联免疫吸附试验(ELISA)试剂盒检测各组血清DcR-3和IL-17浓度,Western blot和免疫荧光染色方法检测脑组织中的DcR-3和IL-17蛋白的表达.结果 胶质瘤患者DcR-3和IL-17在不同的性别、年龄中表达差异无统计学意义(P＞0.05),但与肿瘤病理分级有关,Ⅲ/Ⅳ级胶质瘤患者DcR-3和IL-17表达阳性例数明显高于Ⅰ/Ⅱ级患者(P＜0.01).绝大多数胶质瘤患者DcR-3表达升高伴有IL-17表达阳性.不同级别(Ⅰ、Ⅱ、Ⅲ、Ⅳ)的胶质瘤患者术前血清DcR-3和IL-17浓度均明显高于对照组(P＜0.01).术后DcR-3和IL-17浓度显著降低,Ⅰ～Ⅳ级的胶质瘤患者术前术后DcR-3和IL-17比较差异均有统计学意义(P＜0.01).术前血清DcR-3和IL-17水平与胶质瘤患者预后复发和存活密切相关.存活组胶质瘤患者血清DcR-3和IL-17平均浓度分别为(56.22±18.33)和(72.89士16.58)ng/L,显著低于死亡组[DcR-3和IL-17平均浓度分别为(103.27±10.47)和(121.00±9.02)ng/L,P＜0.01].结论 DcR-3和IL-17表达与人脑胶质瘤的病理分级呈正相关,联合检测血清DcR-3和IL-17浓度有助于胶质瘤患者的诊断、疗效观察和预后判断.
目的 探討誘騙受體-3(DcR-3)和白細胞介素-17(IL-17)在人腦膠質瘤中的錶達及意義.方法 連續收集90例膠質瘤患者及腦外傷患者10例,應用酶聯免疫吸附試驗(ELISA)試劑盒檢測各組血清DcR-3和IL-17濃度,Western blot和免疫熒光染色方法檢測腦組織中的DcR-3和IL-17蛋白的錶達.結果 膠質瘤患者DcR-3和IL-17在不同的性彆、年齡中錶達差異無統計學意義(P＞0.05),但與腫瘤病理分級有關,Ⅲ/Ⅳ級膠質瘤患者DcR-3和IL-17錶達暘性例數明顯高于Ⅰ/Ⅱ級患者(P＜0.01).絕大多數膠質瘤患者DcR-3錶達升高伴有IL-17錶達暘性.不同級彆(Ⅰ、Ⅱ、Ⅲ、Ⅳ)的膠質瘤患者術前血清DcR-3和IL-17濃度均明顯高于對照組(P＜0.01).術後DcR-3和IL-17濃度顯著降低,Ⅰ～Ⅳ級的膠質瘤患者術前術後DcR-3和IL-17比較差異均有統計學意義(P＜0.01).術前血清DcR-3和IL-17水平與膠質瘤患者預後複髮和存活密切相關.存活組膠質瘤患者血清DcR-3和IL-17平均濃度分彆為(56.22±18.33)和(72.89士16.58)ng/L,顯著低于死亡組[DcR-3和IL-17平均濃度分彆為(103.27±10.47)和(121.00±9.02)ng/L,P＜0.01].結論 DcR-3和IL-17錶達與人腦膠質瘤的病理分級呈正相關,聯閤檢測血清DcR-3和IL-17濃度有助于膠質瘤患者的診斷、療效觀察和預後判斷.
목적 탐토유편수체-3(DcR-3)화백세포개소-17(IL-17)재인뇌효질류중적표체급의의.방법 련속수집90례효질류환자급뇌외상환자10례,응용매련면역흡부시험(ELISA)시제합검측각조혈청DcR-3화IL-17농도,Western blot화면역형광염색방법검측뇌조직중적DcR-3화IL-17단백적표체.결과 효질류환자DcR-3화IL-17재불동적성별、년령중표체차이무통계학의의(P＞0.05),단여종류병리분급유관,Ⅲ/Ⅳ급효질류환자DcR-3화IL-17표체양성례수명현고우Ⅰ/Ⅱ급환자(P＜0.01).절대다수효질류환자DcR-3표체승고반유IL-17표체양성.불동급별(Ⅰ、Ⅱ、Ⅲ、Ⅳ)적효질류환자술전혈청DcR-3화IL-17농도균명현고우대조조(P＜0.01).술후DcR-3화IL-17농도현저강저,Ⅰ～Ⅳ급적효질류환자술전술후DcR-3화IL-17비교차이균유통계학의의(P＜0.01).술전혈청DcR-3화IL-17수평여효질류환자예후복발화존활밀절상관.존활조효질류환자혈청DcR-3화IL-17평균농도분별위(56.22±18.33)화(72.89사16.58)ng/L,현저저우사망조[DcR-3화IL-17평균농도분별위(103.27±10.47)화(121.00±9.02)ng/L,P＜0.01].결론 DcR-3화IL-17표체여인뇌효질류적병리분급정정상관,연합검측혈청DcR-3화IL-17농도유조우효질류환자적진단、료효관찰화예후판단.
Objective To study the expression and prognosis value of combined decoy receptor-3 (DcR-3) and interleukin-17 (IL-17) in human gliomas.Methods Ninety patients with gliomas were enrolled and patients suffering from craniocerebral trauma were used as a control group (n =10).The enzyme linked immunosorbent assay (ELISA) kits were used to test the serum concentration of DcR-3 and IL-17 ; Western blotting and immunofluorescence was performed to detect the expression of DcR-3 and IL-17 in both groups.Results DcR-3 and IL-17 expression was increased in astrocytic glioma and was associated with tumor progression,as their expression was increased from grade Ⅱ to grade Ⅳ glioma (P ＜ 0.01),but not with gender or age (P ＞ 0.05).The majority of patients with increased DcR-3 accompanied with elevated IL-17 expression.The preoperative DcR-3 and IL-17 concentration in glioma patients from stage Ⅰ to Ⅳ was significantly increased respectively,each of which was statistically different from that of the controls (P ＜ 0.01).However,both DcR-3 and I L-17 serum level decreased after surgery (P ＜0.01).There was correlation between the preoperative plasma DcR-3 and IL-17 levels and the prognosis for glioma patients.These levels were considerably higher in the decedents than those of the survivors,respectively (P ＜ 0.01).Conclusion The expression of DcR-3 and IL-17 may be correlation to the pathological grades of human gliomas.The combined detection of serum DcR-3 and IL-17 concentration contributes to access gliomas patients diagnosis,therapeutic efficacy and prognosis.
